Skip to main content

Table 3 sLep, sLepR and respective fat mass ratios of RA patients according to BMI and anti-CCP status

From: Serum leptin and serum leptin/serum leptin receptor ratio imbalance in obese rheumatoid arthritis patients positive for anti-cyclic citrullinated peptide antibodies

 

Normal weight

 

Preobese

 

Obese

 

BMI 18.50–24.99 kg/m2

BMI 25.00–29.99 kg/m2

BMI ≥30.00 kg/m2

Anti-CCP

Measurement

Negative

Positive

P

Negative

Positive

P

Negative

Positive

P

n = 6

n = 15

n = 8

n = 13

n = 4

n = 18

sLep, ng/Ml

51.09 ± 29.76

43.93 ± 44.54

0.267

66.90 ± 51.78

155.34 ± 118.56

0.104

104.04 ± 29.21

206.91 ± 101.91

0.033

sLepR, ng/Ml

60.46 ± 14.20

59.82 ± 21.13

0.898

56.47 ± 13.79

48.49 ± 11.55

0.518

45.89 ± 4.63

35.39 ± 9.55

0.101

sLep/sLepR, ng/Ml

0.89 ± .49

1.02 ± 1.69

0.244

1.36 ± 1.43

3.05 ± 2.75

0.240

2.13 ± 0.86

6.55 ± 3.43

0.048

sLep/fat mass, ng/mL/kg

3.44 ± 1.72

2.86 ± 2.08

0.564

2.73 ± 2.30

6.39 ± 4.98

0.053

3.27 ± 0.87

5.77 ± 2.73

0.033

sLepR/fat mass, ng/mL/kg

4.11 ± 1.01

4.78 ± 2.79

0.925

2.25 ± 0.65

1.99 ± 0.43

0.529

1.45 ± 0.27

1.01 ± 0.39

0.101

  1. Continuous variables are represented as mean ± standard deviation; the Mann-Whitney U test was used to compare differences between groups. BMI body bas index, anti-CCP anti-cyclic citrullinated peptide antibodies, sLep serum leptin, sLepR soluble leptin receptor)